Pfizer and Grameen health to improve Bangladeshi health delivery
This article was originally published in Scrip
Pfizerand the micro-financing organisation Grameen Health are to work together to improve healthcare delivery systems and primary care clinics in Bangladesh. The companies expect that if a successful business model is developed, it could then be used in other developing countries. Addressing the needs of those whose annual income is less than $3,000 is a priority of the partnership.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.